Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF

Abstract

We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G-CSF. The in vitro study showed that the leukemic cells separated from this patient expressed G-CSF receptor (G-CSFR) and an addition of G-CSF stimulated their proliferation by 3 H-thymidine incorporation assay (stimulation index, 4.9). To clarify whether or not leukemic cells with 11q23 translocations generally express G-CSFR and show proliferative response to G-CSF, we performed the similar in vitro experiments using eight leukemic cell lines with 11q23 translocations. We found that all cell lines examined expressed G-CSFR (20-98%) and proliferation of seven leukemic cell lines was significantly enhanced in response to G-CSF (stimulation index Ͼ1.5 in five cell lines), suggesting a possible participation of the G-CSF/G-CSFR interaction in the process of growth regulation of leukemic cells with 11q23 translocations.

Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life

“…In none of these patients' leukemia cells did we observe any G-CSF receptor expression. Thus, in contrast to the results of Inukai et al, 2 G-CSF-receptor expression and 11q23/MLL rearrangements were not inextricably linked in our patient population. Since our patients expressing the G-CSF receptor were treated within the intermediate risk group of the ALL-BFM 90 study, they did not receive recombinant human G-CSF during the treatment period.…”

The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome

“…All cell lines other than NALM1, NALM6, and Jurkat were established in our laboratory and have been described previously. [21][22][23][24] Mononuclear cells separated from cord blood (CB-MNC) were used as a source of hematopoietic stem cells in colony-forming assays. …”

Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial

“…10 Furthermore, in vitro data have suggested, that G-CSF could enhance the regrowth of leukemic cells and favor relapse of disease after BMT. 11,12 Therefore, it seems advisable to minimize the duration of treatment with G-CSF without reducing the benefit of accelerated hematological recovery due to G-CSF.…”